CT-P13 SC (Infliximab)

BIOLOGICAL4 trials

Sponsors

Katsuyoshi Matsuoka, Matsuoka Katsuyoshi, Celltrion

Conditions

Crohn Disease Crohn DiseaseCrohn's DiseaseUlcerative Colitis

Phase 3

CT-P13 (Infliximab) Subcutaneous Administration in Patients With Moderately to Severely Active Crohn's Disease (LIBERTY-CD)

CompletedNCT03945019

CelltrionCrohn's Disease

Start: 2019-10-28End: 2023-08-22Updated: 2023-10-23

CT-P13 (Infliximab) Subcutaneous Administration in Patients With Moderately to Severely Active Ulcerative Colitis (LIBERTY-UC)

CompletedNCT04205643

CelltrionUlcerative Colitis

Start: 2020-09-01End: 2023-07-11Updated: 2023-09-28

Single-arm, Open-label, Phase 3, Multi-center Study to Evaluate the Safety and Efficacy of the Subcutaneous Injection of CT-P13 (CT-P13 SC) as Maintenance Therapy in Patients with Crohns Disease in Japan

Active, not recruitingJPRN-jRCT2031230707

Katsuyoshi MatsuokaCrohn Disease Crohn Disease

Start: 2024-04-01Target: 60Updated: 2026-06-29

Single-arm, Open-label, Phase 3, Multi-center Study to Evaluate the Efficacy and Safety of the Subcutaneous Injection of CT-P13 (CT-P13 SC) as Maintenance Therapy in Patients with Ulcerative Colitis in Japan

Active, not recruitingJPRN-jRCT2031250197

Matsuoka KatsuyoshiUlcerative Colitis

Start: 2025-08-25Target: 47Updated: 2026-06-29

Related Papers

Symptom Response Dynamics for Personalised Therapy with Subcutaneous Infliximab in Crohn's Disease: Insights from the Randomised, Placebo-Controlled, Phase 3 LIBERTY-CD Trial.

2026-03-30

Recovery of response and long-term outcomes following loss of response and dose escalation of subcutaneous infliximab: a post hoc analysis of the LIBERTY-CD & LIBERTY-UC trials.

2026-03-18

Subcutaneous infliximab (CT-P13 SC) as maintenance therapy for Crohn’s disease and ulcerative colitis: 2-year results from open-label extensions of two randomized controlled trials (LIBERTY)

Journal of Crohn s and Colitis2025-04-173 citations

IMPACT OF IMMUNOGENICITY ON CLINICAL OUTCOMES IN PATIENTS WITH ULCERATIVE COLITIS RECEIVING MAINTENANCE TREATMENT WITH SUBCUTANEOUS INFLIXIMAB: A POST HOC ANALYSIS OF THE LIBERTY-UC STUDY

Inflammatory Bowel Diseases2025-02-01

Subcutaneous Infliximab (CT-P13 SC) as Maintenance Therapy for Inflammatory Bowel Disease: Two Randomized Phase 3 Trials (LIBERTY).

2024-05-2342 citations

P1074 Impact of body mass index (BMI) on clinical outcomes and drug levels in patients with Crohn’s disease receiving maintenance treatment with subcutaneous infliximab: A post hoc analysis of the LIBERTY-CD study

Journal of Crohn s and Colitis2024-01-013 citations

P874 Impact of immunogenicity on clinical outcomes in patients with Crohn’s disease receiving maintenance treatment with subcutaneous infliximab: A post hoc analysis of the LIBERTY-CD study

Journal of Crohn s and Colitis2024-01-013 citations

P957 Subcutaneous infliximab (CT-P13 SC) for ulcerative colitis: 2-year extension results of the LIBERTY-UC study

Journal of Crohn s and Colitis2024-01-012 citations

P734 Super-responders in patients with moderate-to-severe Crohn’s disease treated with subcutaneous infliximab maintenance therapy: A post hoc analysis of the LIBERTY-CD study

Journal of Crohn s and Colitis2024-01-012 citations

DOP86 Subcutaneous infliximab (CT-P13 SC) as maintenance therapy for Crohn’s disease: A phase 3, randomised, placebo-controlled study (LIBERTY-CD).

Journal of Crohn s and Colitis2023-01-3021 citations

P492 Subcutaneous infliximab (CT-P13 SC) as maintenance therapy for ulcerative colitis: A Phase 3, randomized, placebo-controlled study: Results of the LIBERTY-UC study

Journal of Crohn s and Colitis2023-01-3020 citations